These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 27262526)
21. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Tang SS; Apisarnthanarak A; Hsu LY Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490 [TBL] [Abstract][Full Text] [Related]
22. What is an "ideal" antibiotic? Discovery challenges and path forward. Singh SB; Young K; Silver LL Biochem Pharmacol; 2017 Jun; 133():63-73. PubMed ID: 28087253 [TBL] [Abstract][Full Text] [Related]
23. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective. Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints. Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506 [TBL] [Abstract][Full Text] [Related]
25. Emerging resistance in Gram-negative pathogens and implications for clinical practice. Cantón R; Lumb J Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632 [TBL] [Abstract][Full Text] [Related]
27. New trends in pharmacogenomic strategies against resistance development in microbial infections. Ohlsen K; Dandekar G; Schwarz R; Dandekar T Pharmacogenomics; 2008 Nov; 9(11):1711-23. PubMed ID: 19018725 [TBL] [Abstract][Full Text] [Related]
28. Cracking the regulatory code of biosynthetic gene clusters as a strategy for natural product discovery. Rigali S; Anderssen S; Naômé A; van Wezel GP Biochem Pharmacol; 2018 Jul; 153():24-34. PubMed ID: 29309762 [TBL] [Abstract][Full Text] [Related]
29. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. Monogue ML; Kuti JL; Nicolau DP Expert Rev Clin Pharmacol; 2016; 9(3):459-76. PubMed ID: 26678036 [TBL] [Abstract][Full Text] [Related]
30. [The rise of resistant gram-negative bacteria]. Kuijper EJ; van Dissel JT Ned Tijdschr Geneeskd; 2010; 154(45):A2868. PubMed ID: 21118590 [TBL] [Abstract][Full Text] [Related]
31. Multidrug-resistant Gram-negative infections: the use of colistin. Michalopoulos AS; Karatza DC Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945 [TBL] [Abstract][Full Text] [Related]
32. Multidrug-Resistant Gram-Negative Organisms (MDRGNO) Information for patients, relatives and visitors. J Hosp Infect; 2016 Jan; 92(1):88-91. PubMed ID: 27158704 [No Abstract] [Full Text] [Related]
33. Editorial: Resistance in gram-negative pathogens: a threat to global health. Hanson ND Curr Pharm Des; 2013; 19(2):163. PubMed ID: 22920832 [No Abstract] [Full Text] [Related]
35. Mechanism and Potential Inhibitors of GlmU: A Novel Target for Antimicrobial Drug Discovery. Sharma R; Khan IA Curr Drug Targets; 2017; 18(14):1587-1597. PubMed ID: 27138757 [TBL] [Abstract][Full Text] [Related]
36. Renew or die: The molecular mechanisms of peptidoglycan recycling and antibiotic resistance in Gram-negative pathogens. Domínguez-Gil T; Molina R; Alcorlo M; Hermoso JA Drug Resist Updat; 2016 Sep; 28():91-104. PubMed ID: 27620957 [TBL] [Abstract][Full Text] [Related]
37. Novel Antibacterial Compounds and their Drug Targets - Successes and Challenges. Kaczor AA; Polski A; Sobótka-Polska K; Pachuta-Stec A; Makarska-Bialokoz M; Pitucha M Curr Med Chem; 2017; 24(18):1948-1982. PubMed ID: 27978802 [TBL] [Abstract][Full Text] [Related]